Bridging research and policy: To improve children in child welfare’s behavioral health

Sarah Zlotnik, MSW, MSPH
October 19th, 2012
Today’s talk

• Overview PolicyLab’s approach to bridging research and policy

• Highlight PolicyLab’s research on the behavioral health of children in child welfare
PolicyLab
at The Children’s Hospital of Philadelphia

“Evidence to Action”
PolicyLab is engaged in projects across several domains of child health

For more information, please visit www.research.chop.edu/policylab
The increasing use of psychototropic medications
PolicyLab’s psychotropic medication study

Population data

- National sample of Medicaid data, 2002-2009
- To determine trends in pediatric psychotropic medication use over time across all 50-states
  - Polypharmacy & antipsychotic medication use
  - Medicaid and foster care specific analyses
- AHRQ funded
- Led by David Rubin, MD, MSCE & Meredith Matone, MHS
PolicyLab’s psychotropic medication study

*Policy analysis*

- Identify system-level factors influence exposure to psychotropic medication among children
- 16-state legal and policy review on:
  - Oversight & Red flags
  - Consent
  - Screening and Assessment
- Led by Kathleen Noonan, JD
Trajectories of psychotropic medication use by medication class

Rx Use by Year and Class

Probability of Rx Use

year

2002 2003 2004 2005 2006 2007

Antidep  Stim  Mood  Antipsy
Increasing antipsychotic use in foster care

Increasing antipsychotic use in foster care

Increasing antipsychotic use in foster care

Increasing antipsychotic use in foster care

Increasing antipsychotic use in foster care

Increasing antipsychotic use in foster care

THE POPULATION PERSPECTIVE:

Frequently diagnosed conditions without clinical indication for antipsychotics account for the majority of children’s antipsychotic use.

- ADHD
- Bipolar
- Child on antipsychotics

Children with ADHD are prescribed antipsychotics at less than one-third the rate of children with bipolar disorder (17% vs. 60%).

However, the high prevalence of ADHD makes children with this diagnosis the largest population of antipsychotic users.
What can we do?
Strengthening psychotropic medication oversight

- To develop oversight parameters and guidance in accordance with *2011 Child and Families Services Improvement and Innovation Act*

- Who are the people to act on the data?
  - ACYF and HHS psychotropic medication working group
  - State child welfare, Medicaid, and mental health
  - Pennsylvania
Increasing access to evidence-based non pharmacological behavioral therapy

- Need to ensure timely access
- Need to be sustained by ongoing training, sufficient reimbursement, public system scale up

PolicyLab Example:
- Implementation and evaluation of an evidence-based behavioral health intervention in the City of Philadelphia
  - Using Parent Child Interaction Therapy
Concluding remarks

- PolicyLab: EVIDENCE TO ACTION
  - Linking research and policy
  - Ensuring the accessibility of the data
  - Building partnerships with local, state and federal decision makers
  - Strengthening public systems on the ground
Trends in antipsychotic use across time